Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos    GLPG   BE0003818359

GALAPAGOS

(GLPG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
156.55(c) 156.45(c) 152.05(c) 152.4(c) 154.85(c) Last
275 745 291 538 332 175 330 438 427 072 Volume
-0.48% -0.06% -2.81% +0.23% +1.61% Change
More quotes
Financials (EUR)
Sales 2019 724 M
EBIT 2019 267 M
Net income 2019 277 M
Finance 2019 4 724 M
Yield 2019 -
Sales 2020 565 M
EBIT 2020 5,23 M
Net income 2020 33,5 M
Finance 2020 4 598 M
Yield 2020 -
P/E ratio 2019 71,2x
P/E ratio 2020 299x
EV / Sales2019 5,20x
EV / Sales2020 6,88x
Capitalization 8 489 M
More Financials
Company
Galapagos specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales (including intra-group) break down by activity as follows: - discovery and development of drugs (93,1%); - other (6,9%). Net sales are distributed... 
More about the company
Surperformance© ratings of Galapagos
Trading Rating : Investor Rating :
More Ratings
Latest news on GALAPAGOS
08/16GILEAD SCIENCES : European Medicines Agency Validates Marketing Application for ..
AQ
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/15GALAPAGOS : European Medicines Agency Validates Marketing Application for Filgot..
BU
08/15European medicines agency validates marketing application for filgotinib..
GL
07/25GALAPAGOS : Strong clinical progress in H1 and transformative collaboration with..
GL
07/15S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Circor and Callon fall while Galapagos, Omnicell rise
AQ
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15MARKET SNAPSHOT: Stocks Eke Out Another Round Of Records As Investors Brace F..
DJ
More news
Analyst Recommendations on GALAPAGOS
More recommendations
Sector news : Biotechnology & Medical Research - NEC
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart GALAPAGOS
Duration : Period :
Galapagos Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 162,67  €
Last Close Price 154,85  €
Spread / Highest target 25,9%
Spread / Average Target 5,05%
Spread / Lowest Target -30,3%
EPS Revisions
Managers
NameTitle
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Operating & Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS92.22%9 277
IQVIA HOLDINGS INC33.61%29 805
LONZA GROUP34.43%25 750
INCYTE CORPORATION30.71%17 337
CELLTRION, INC.--.--%16 155
EXACT SCIENCES CORPORATION87.35%15 308